Professor Emeritus Malcolm Rowland (Chairman)

Professor Rowland joined the Xceleron Scientific Advisory Board as its Chair in 2006. He is a recognised world expert in physiologically based pharmacokinetics with a broad experience of its industrial application to drug discovery and development,. He serves on several European, American and International advisory boards and committees, and is an advisor to Pharma. He has authored some 300 scientific papers covering the fields of basic and clinical pharmacokinetics, is a co-author of the textbooks Clinical Pharmacokinetics: Concepts and Applications, and Introduction to Pharmacokinetics and Pharmacodynamics, and was a founder and the Editor of the Journal of Pharmacokinetics and Pharmacodynamics (1973-2006). He has also established European and U.S. workshops for teaching of both basic and advanced pharmacokinetics.

Professor Joseph P. Balthasar

Professor Joseph P. Balthasar is Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Professor Balthasar received a B.S. in Pharmacy (1991) and a Ph.D. in Pharmaceutics (1996) from the University at Buffalo. Prior to joining the faculty of the University as an Assistant Professor in 1999, Professor Balthasar served as a Clinical Assistant Professor of Pharmaceutics at the University at Buffalo from 1996-1997 and, from 1997-1999, as an Assistant Professor of the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Professor Balthasar’s research, which is funded by the National Institutes of Health, utilizes pharmacokinetic and pharmacodynamic analyses to guide the development of new therapies. Current research focuses on the development of drug targeting strategies to improve the selectivity of cancer chemotherapy and on the development of new immunotherapies for the treatment of humoral autoimmune diseases.

Graham Lappin, Ph.D.

Dr Graham Lappin is Senior Director of Science and Technology at Xceleron. Dr Lappin received his BSc in Biochemistry (1981) and PhD (1984) from the University of Westminster (London UK). Following this he spent two years at the University of Glasgow researching into the anabolism of terpenoids in plant species. Following a period developing analytical methods for mass spectrometry, Dr Lappin joined ICI in Manchester in 1989 (later to become Zeneca and then Astra-Zeneca). Here he led a team of scientists researching into the metabolism of xenobiotics in laboratory animal species and later also managed the Mass Spectroscopy Unit. He left in 1995 to join Covance Laboratories (Harrogate UK) as a Section Manger in the Metabolism and Environmental Chemistry Department. Dr Lappin continued his work on xenobiotic metabolism in laboratory animals and human volunteers, extending this to setting up and running studies on in vivo and in vitro dermal absorption. In 2001, he joined Xceleron as Head of Research and Development. Here he has helped pioneer many applications of Accelerator Mass Spectrometry, including Human Microdosing. In 2006, he published a text book on the use of Radiotracers in Drug Development (CRC Taylor Francis). At the end of 2008, he became Xceleron’s head of science as Senior Director for Science and Technology and began a secondment to Xceleron’s facility in Maryland in the United States. Dr Lappin lectures at the University of York and is a Fellow of the Institute of Biology and Royal Society of Chemistry in the UK. He has served on the Institute of Biology’s Council as well as the Royal Society’s International Scientific Unions’ Committee and is on the editorial board for Expert Opinion in Drug Metabolism and Toxicology. Graham sits on the Scientific Advisory Board of the Human Regenerate Map Project at the Karolinska Institute In Stockholm, Sweden (www.thrm.ki.se/).